Oral ruxolinitib effect on alopecia areata patients: scalp skin
Summary:
Analysis of scalp skin from two alopecia areata (AA) patients treated with oral ruxolitinib for 12 weeks. AA is a T-cell mediated autoimmune disease. Ruxolitinib is a small-molecule inhibitor of the JAK1/2 kinases. Results provide insight into molecular mechanisms underlying the pathogenesis of AA.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Xing L, Dai Z, Jabbari A, Cerise JE et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014 Sep;20(9):1043-9. PMID: 25129481
